"10.1371_journal.pone.0112359","plos one","2014-11-12T00:00:00Z","Trygve Husebye; Jan Eritsland; Harald Arnesen; Reidar Bjørnerheim; Arild Mangschau; Ingebjørg Seljeflot; Geir Øystein Andersen","Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; Center for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway","Contributed to the writing of the manuscript: TH JE HA RB AM IS GØA. Conceived and designed the experiments: JE HA RB AM IS GØA. Performed the experiments: TH JE AM RB GØA. Analyzed the data: TH JE HA RB IS GØA. Contributed reagents/materials/analysis tools: RB IS GØA.","The Department of Cardiology, Oslo University Hospital received an unrestricted educational grant from the manufacturer of levosimendan, Orion Pharma in 2005. Orion Pharma did not provide study medication or have any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. T. Husebye received in 2012 a lecture honorarium from Orion Pharma. All other authors have declared that no competing interests exist. This does not alter the authors adherence to all PLOS ONE policies on sharing data and materials.","2014","11","Trygve Husebye","TH",7,FALSE,6,5,6,NA,TRUE,TRUE,FALSE,0,NA,FALSE
